Overview

A Prevention Trial of Canakinumab in Subjects at High Risk for Lung Cancer

Status:
Terminated
Trial end date:
2022-09-21
Target enrollment:
Participant gender:
Summary
Randomized phase III, double-blind, placebo-controlled, multicenter clinical trial.
Phase:
Phase 3
Details
Lead Sponsor:
Mario Negri Institute for Pharmacological Research
Collaborator:
Novartis Pharmaceuticals